Tag Archives: Active Pharmaceutical Ingredient Market

Active Pharmaceutical Ingredient Market Outlook Key Analysis and Forecast by 2023

Climbing Numbers of Chronic Conditions Drive API Market

The growing pool of geriatrics is driving the demand for various types of drugs, which in turn is leading to a soaring demand of active pharmaceutical ingredient (API) market. Active pharmaceutical ingredients are primarily used for making drugs that are used for treating a range of chronic conditions such as cancer, metabolic disorders, cardiovascular diseases, neurology disorders as well as for other therapeutic uses. Given this strong background, Transparency Market research states the opportunity in this market will be worth US$219.60 bn by 2023 from US$134.7 bn in 2015. Between the forecast period of 2015 and 2023, the overall market is expected to expand at a CAGR of 6.3%.

This 115 page report gives readers a comprehensive overview of the Active Pharmaceutical Ingredient Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html

The improving access to healthcare with the rapid penetration of technology and other developments in the healthcare sector has also increased the consumption of drugs, thereby directly creating a positive impact on this market. Furthermore, growing healthcare budgets of developed and developing countries are also making a significant contribution towards propelling the sale of API market. Furthermore, the compliance by Indian active pharmaceutical ingredients manufacturers with U.S. FDA norms is also anticipated to result in increasing applications of this substance.

Complicated Cardiovascular Diseases to Keep Fueling Demand for APIs

As of 2015, the high incidence of cardiovascular diseases, neurological disorders, and other metabolic disorders led these therapeutic segments to account for a collective share of 50% in the global market. In the forecast period, the prevalence of complicated cardiovascular conditions is going to propel this therapeutic area at a 6.63% CAGR. Furthermore, as the majority of the blockbuster drugs lost patents between 2011 and 2015, it has opened a huge ground for other companies to introduce their drugs, thereby increasing the competition and probably reducing costs.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Active Pharmaceutical Ingredient Market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1690

Asia Pacific to Emerge as Key Manufacturer of APIs

As of 2014, North America held a dominant share in the overall market, accounting for about 35.1% share in the market. The presence of big pharmaceutical companies in North America that require large amounts of active pharmaceutical ingredients is the major factor driving the API market in North America. Analysts predict that introduction of biosimilars as the regulatory process get relaxed will further accelerate the consumption of active pharmaceutical ingredients in North America. The API manufacturing will experience an upsurge in the emerging economies of Japan, China, South Korea, and India due to the presence of manufacturing facilities and cheap cost of labor.

Some of the leading companies operating in the global active pharmaceutical ingredient market are Zhejiang Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., Zhejiang NHU Co., Ltd , North China Pharmaceutical Group Corp. (NCPC), Dr.Reddy’s Laboratories Limited, Northeast Pharmaceutical Group Co., Ltd., Aurobindo Pharma Limited, Sandoz (Novartis AG), Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. amongst others. Currently, these players are focusing on partnering with other companies to acquire a new line of products to add value to their portfolio. Furthermore, companies are also anticipated to focus on expanding their capacities to cater to the vast unmet medical needs of the world.

 

Active Pharmaceutical Ingredient Market: Impact of Key Factors Influencing the Parent Industry

The leading companies operating in the active pharmaceutical ingredients (API) market are Zhejiang NHU Co., Ltd., Teva Pharmaceutical Industries Ltd., Zhejiang Medicine Co., Ltd., Northeast Pharmaceutical Group Co., Ltd., and North China Pharmaceutical Group Corp. and they accounted for the major combined share in 2015. Transparency Market Research (TMR) observes that the top players are opting for strategic mergers and acquisitions to consolidate their shares. The presence of significant barriers to exit and high fixed costs incurred by companies have intensified the competitive landscape in the market.

In order to cut down manufacturing costs, a growing number of pharmaceutical companies, especially in Europe and North America, prefer to outsource manufacturing overseas. These companies which previously had manufacturing units in their home countries are increasingly shifting to regions with cheap availability of labor and raw materials. However, these APIs are subject to stringent regulations of the countries where the pharmaceutical companies are housed. In addition, several players are focusing on research and development activities to develop innovative formulations, notes TMR. The opportunity in the global active pharmaceutical ingredient market stood at US$134.70 bn in 2015. Rising at a CAGR of 6.3% from 2015 to 2023, the market is expected to reach a valuation of US$219.60 bn by the end of 2023.

This 115 page report gives readers a comprehensive overview of the Active Pharmaceutical Ingredient Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html

Asia Pacific Offers Lucrative Growth Avenues to API Manufacturers

Geographically, North America is the leading market as it accounted for a major share in the global market in 2015. The dominance of this regional market is attributed to the large presence of pharmaceutical companies which require premium quality of APIs. However, in the coming years, Asia Pacific is fast emerging as the major hub for API sourcing driven by cost reduction in manufacturing.

Based on therapeutic areas, the cardiovascular disorders segment dominates the market and is projected to expand at a CAGR of 6.63% from 2015 to 2023. The growing prevalence of various cardiac conditions with complicated etiology is expected to boost the active pharmaceutical ingredient market through the forecast period. A number of blockbuster drugs going off-patents is further expected to stimulate the demand for APIs.

Growing Prevalence of Chronic Conditions to Fuel Market

The active pharmaceutical ingredient market is majorly driven by the growing prevalence of a variety of chronic conditions such as cancer, cardiovascular disorders, metabolic disorders, and neurological disorders. Increasing incidence of these diseases has propelled the demand for therapeutics and novel therapies. This has spurred research in drug formulation for more efficacious treatments. In addition, the rapidly growing geriatric population, especially in developed regions of North America and Europe, is expected to stimulate the demand for APIs in making therapies for various ailments.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Active Pharmaceutical Ingredient Market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1690

Improving access to quality healthcare in developing regions such as Asia Pacific has propelled the demand for APIs in these regions. In addition, investment by API manufacturers in Asia to adhere to the regulatory compliance requirements, coupled with the tightening regulations by the U.S. FDA on the efficacy of APIs, is expected to boost the global market. However, the growing popularity of generic drugs in developing and resource-poor nations is expected to affect the profit margins of API manufacturers. Nevertheless, various regulatory agencies are working actively to address these concerns, which is expected to unlock exciting opportunities for market players. Substantial spending by various pharmaceutical companies to bolster capacity of API production are also likely to create new opportunities in the market.

The study presented here is based on a report by Transparency Market Research (TMR) titled “Active Pharmaceutical Ingredients (API) Market (Manufacturing Process – Captive Manufacturing and Contract Manufacturing; API Type – Synthetic Chemical API and Biological API; Drug Type – Branded Prescription Drugs, Generic Prescription Drugs, and OTC Prescription Drugs; Therapeutic Area – Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncology, Musculoskeletal Disorders, and NSAIDs) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.”

 

Active Pharmaceutical Ingredient Market Trends And Opportunities For The Industry By 2023

This report on global X-ray photoelectron spectroscopy (XPS) market analyzes the current and future prospects of the XPS technology worldwide. The stakeholders of this report include companies engaged in production and marketing of XPS systems across the globe. This report encompasses an elaborate executive summary, with a market snapshot that provides overall information of major market segments and sub-segments included in the study scope. This section also provides the overall information and data analysis of the market with respect to the leading market segments based on analysis and major application areas.

This 115 page report gives readers a comprehensive overview of the Active Pharmaceutical Ingredient Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html

The global market has been segmented on the basis of analysis, application, and geography. The analysis segment has been further segmented into forensic analysis, contamination analysis, elemental analysis, electronic density estimation, and others. XPS market finds application majorly in healthcare, semiconductor and electronics and other industries. Increasing use of XPS technology in medical and pharmaceutical research for determination of drug safety and efficiency in conjunction with increasing support from respective nation’s government to promote awareness about these technology platforms ensure lucrative growth opportunity for this market. Application of XPS technology in healthcare industry is anticipated to record highest growth rate during the coming years. Geographically, global XPS market has been further categorized into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America dominated the global market in terms of market share and is expected to retain its position throughout next few years. This is majorly attributed to increasing preference for the use of high end technological platforms coupled with increased awareness levels of people with respect to their health, lifestyle and environment. The market for each of these segment has been analyzed on the basis of various market dynamics such as technological advances, its advantages and increasing use of the innovative techniques in many research activities. Market revenue in terms of US$ Mn for the period between 2013 and 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all the segments, considering 2014 as the base year.

The market overview section of this report explores market dynamics such as drivers, restraints, and opportunities that have predominant impact on this market at present and could influence the market in the future as well. The market attractiveness analysis has been provided in the market overview section in order to elucidate the intensity of competition in the market in different LATAM countries. Porter’s five forces analysis is also explained in this section to understand the XPS market considering different parameters that have an impact on the sustainability of the companies operating in this market. The competitive scenario between different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help the market players to take strategic decisions in order to strengthen their positions and expand their shares worldwide.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Active Pharmaceutical Ingredient Market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1690

The report also profiles major players in the XPS market on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Some of the major players profiled in this report include Thermo Fisher Scientific, Kratos Analytical, Japan Electron Optics Lab (JOEL), and Evans Analytical Group (EAG) among others. Rigorous research and development initiatives by the leading market players as well as execution of unique marketing strategies to increase the accessibility and affordability towards these technologies are supporting the XPS market growth globally. The global XPS market is influenced by the presence of large regional players and predominant in developed economies as compared to other developing economies. However, these companies are focusing on expansion in emerging economies especially in countries like India, China and Australia.

 

Active Pharmaceutical Ingredient Market 2015 – Industry Perspective and Comprehensive Analysis 2023

The leading companies operating in the active pharmaceutical ingredients (API) market are Zhejiang NHU Co., Ltd., Teva Pharmaceutical Industries Ltd., Zhejiang Medicine Co., Ltd., Northeast Pharmaceutical Group Co., Ltd., and North China Pharmaceutical Group Corp. and they accounted for the major combined share in 2015. Transparency Market Research (TMR) observes that the top players are opting for strategic mergers and acquisitions to consolidate their shares. The presence of significant barriers to exit and high fixed costs incurred by companies have intensified the competitive landscape in the market.

In order to cut down manufacturing costs, a growing number of pharmaceutical companies, especially in Europe and North America, prefer to outsource manufacturing overseas. These companies which previously had manufacturing units in their home countries are increasingly shifting to regions with cheap availability of labor and raw materials. However, these APIs are subject to stringent regulations of the countries where the pharmaceutical companies are housed. In addition, several players are focusing on research and development activities to develop innovative formulations, notes TMR. The opportunity in the global active pharmaceutical ingredient market stood at US$134.70 bn in 2015. Rising at a CAGR of 6.3% from 2015 to 2023, the market is expected to reach a valuation of US$219.60 bn by the end of 2023.

This 115 page report gives readers a comprehensive overview of the Active Pharmaceutical Ingredient Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html

Asia Pacific Offers Lucrative Growth Avenues to API Manufacturers

Geographically, North America is the leading market as it accounted for a major share in the global market in 2015. The dominance of this regional market is attributed to the large presence of pharmaceutical companies which require premium quality of APIs. However, in the coming years, Asia Pacific is fast emerging as the major hub for API sourcing driven by cost reduction in manufacturing.

Based on therapeutic areas, the cardiovascular disorders segment dominates the market and is projected to expand at a CAGR of 6.63% from 2015 to 2023. The growing prevalence of various cardiac conditions with complicated etiology is expected to boost the active pharmaceutical ingredient market through the forecast period. A number of blockbuster drugs going off-patents is further expected to stimulate the demand for APIs.

Growing Prevalence of Chronic Conditions to Fuel Market

The active pharmaceutical ingredient market is majorly driven by the growing prevalence of a variety of chronic conditions such as cancer, cardiovascular disorders, metabolic disorders, and neurological disorders. Increasing incidence of these diseases has propelled the demand for therapeutics and novel therapies. This has spurred research in drug formulation for more efficacious treatments. In addition, the rapidly growing geriatric population, especially in developed regions of North America and Europe, is expected to stimulate the demand for APIs in making therapies for various ailments.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Active Pharmaceutical Ingredient Market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1690

Improving access to quality healthcare in developing regions such as Asia Pacific has propelled the demand for APIs in these regions. In addition, investment by API manufacturers in Asia to adhere to the regulatory compliance requirements, coupled with the tightening regulations by the U.S. FDA on the efficacy of APIs, is expected to boost the global market. However, the growing popularity of generic drugs in developing and resource-poor nations is expected to affect the profit margins of API manufacturers. Nevertheless, various regulatory agencies are working actively to address these concerns, which is expected to unlock exciting opportunities for market players. Substantial spending by various pharmaceutical companies to bolster capacity of API production are also likely to create new opportunities in the market.

The study presented here is based on a report by Transparency Market Research (TMR) titled “Active Pharmaceutical Ingredients (API) Market (Manufacturing Process – Captive Manufacturing and Contract Manufacturing; API Type – Synthetic Chemical API and Biological API; Drug Type – Branded Prescription Drugs, Generic Prescription Drugs, and OTC Prescription Drugs; Therapeutic Area – Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncology, Musculoskeletal Disorders, and NSAIDs) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.”

 

Active Pharmaceutical Ingredient Market: Impact of Key Factors Influencing the Parent Industry

Active Pharmaceutical Ingredient (API) refers to a substance or substance combination used in manufacturing a drug product. The active pharmaceutical ingredient market has been categorized by manufacturing process, API type, drug type, therapeutic area and geography. Manufacturing processes in the global API market include captive and contract manufacturing. The captive API manufacturing segment comprises the active pharmaceutical ingredients produced for internal consumption of a pharmaceutical company. Captive manufacturing accounted for the highest market share in 2014, however the share of this market segment is expected to witness a decline due high degree of competition from contract manufacturing and reduced profitability and thus increased preference for outsourcing API production over captive production. Outsourcing production helps pharmaceutical companies focus on their core business of developing new drug products. Contract manufacturing is being preferred because of its advantage in terms of capital and labor costs, access to advanced manufacturing technologies, and benefits from the global distribution network.

This 115 page report gives readers a comprehensive overview of the Active Pharmaceutical Ingredient Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html

The global active pharmaceutical market is segmented into API types: synthetic chemical API and biological API. The synthetic chemical API segment held the largest share of more than 70% of active pharmaceutical market in 2014. This market segment has evolved in the past few years due to innovations in the methods of synthesizing chemical APIs, which improves their stability and potency. The large volume of the demand is an important reason for the larger share of synthetic chemical API segment. On the other hand, the biological API market segment is expected to have the highest growth rate of 8.1% during the forecast period of 2015-2023. Large pharmaceutical companies are scaling down their small molecule manufacturing facilities to focus on biologic drugs, thereby presenting greater opportunities for contract manufacturing companies. The overall cost of drug development program for biologics is less as compared to chemical APIs, primarily because of high success rates in the pipeline phase. This factor has attracted higher investments in the biologics and biosimilars market.

Drug types in the global API market include branded prescription drug, generic prescription drug and OTC drugs. The branded API segment accounted for the largest share of 76% in the global API market in 2014. The factors driving the branded prescription drugs include government initiatives that has lowered the copayment on generics while raising it on the branded drugs. The increasing demand for biological drugs and supportive policies of the European Union toward biosimilars is also one of the major driving factors to boost branded API market. Moreover, the generic prescription drugs segment is expected to grow at the highest rate of 7.3% during the forecast period. With the rising cost of healthcare, governments and payers are pushing for the increasing generics consumption over branded drugs, thus driving growth of the generic APIs market. Over-the-counter (drugs) are considered sufficiently safe and effective for use without prescriptions from health care professionals and hence would continue to grow at a steady rate during the forecast period.

Based on the therapeutic area, the global API market is segmented into various disorders such as cardiovascular, metabolic, disorders, oncology, musculoskeletal, non-steroidal anti-inflammatory drugs (NSAIDs), and others. The cardiovascular disorder segment held the largest share of global active pharmaceutical ingredient market during the forecast period. Cardiovascular, metabolic, and neurological disorders held a combined market share of over 50% in 2014 due to the rising geriatric population, increasing prevalence of cardiovascular diseases, diabetes and neurological disease globally. Whereas, the oncology segment is expected to grow at the highest rate of 8.2% during the forecast period owing to the rising prevalence of cancer. The significant growth observed in oncology API has helped companies to prefer specialized manufacturing plants for oncology drugs. The musculoskeletal disorders, NSAIDs and other therapeutics area is anticipated to grow at a steady rate during the forecast period of 2015 to 2023.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving

Active Pharmaceutical Ingredient Market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1690

Geographically, North America dominated the active pharmaceutical ingredient market in 2014 with a share of 35.1% owing to factors such as higher consumption of API due to the presence of major pharmaceutical companies in this region. Biologics have become one of the top-selling drugs in North America. Thus, the expected market entry of biosimilars with flexible regulatory process would further boost the API market in North America. Japan, China, India and South Korea, the leading pharmaceutical hubs in Asia are majorly responsible for almost 30% of the total market share placing the region at the second position in the world. Major factors driving the API markets in China and India are the availability of low cost production facilities and labor cost. Other factors driving the market in the region include the tax incentives, rising government expenditure on health care and government plans to restructure the fragmented industry. Europe accounted for a market share of 21.6% in 2014. The governments of various countries in Europe have started supporting the manufacture of generic drugs post the financial crisis. Patent expirations of major blockbuster drugs in Europe would fuel the growth of the API market in the near future. Demand for generic drugs is increasing not only in developed countries, but also in developing and underdeveloped countries in South America and Africa. Brazil and South Africa are the important centers of pharmaceutical manufacturing in this regional segment. Factors boosting the growth of the market in developing regions are cost-efficient manufacturing, large number of patients, rising demand for generic drugs, and improvement in the healthcare infrastructure.

Teva Pharmaceutical Industries Ltd dominated active pharmaceutical ingredients market in 2014. Major factors attributed to its dominance are broad product portfolio and high market penetration. Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd secured the second market position in 2015. North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. held the third position in 2015. Other players in the active pharmaceutical ingredients market include Dr.Reddy’s Laboratories Limited, Sandoz (Novartis AG), Aurobindo Pharma Limited, Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. and others.